Broadwood urges STAAR shareholders to reject $28 per share Alcon deal
NegativeFinancial Markets

Broadwood Capital is urging STAAR Surgical shareholders to reject the proposed $28 per share deal with Alcon, arguing that the offer undervalues the company. This matters because it highlights the ongoing tension between shareholders and management regarding the true worth of STAAR, potentially impacting its future direction and investment strategies.
— Curated by the World Pulse Now AI Editorial System